RACGAP1 and breast carcinoma: In the present study, we sought to develop a risk for recurrence score (RRS) based on three proliferation markers, e.g. RACGAP1, TOP2A and Ki67, in high-risk early breast cancer patients and evaluate its ability to predict risk for relapse and death.